

# THE SILENT PANDEMIC

Addressing Antimicrobial Resistance Through a Sustainable Marketplace



## THE THREAT OF ANTIMICROBIAL RESISTANCE

A shortage of effective antibiotics puts the world at risk for future pandemics. A recent study in *The Lancet* estimates that in 2019, more people died from an antibiotic-resistant infection than from HIV/AIDS or malaria.

THE GLOBE

**1.27 MILLION**

PEOPLE DIE

from drug-resistant infections every year

**10 MILLION**

POTENTIAL DEATHS

from drug-resistant infections by 2050

THE U.S.

**35,000**

AMERICANS DIE

from drug-resistant infections every year

**2.8 MILLION**

AMERICANS ARE INFECTED

by antibiotic-resistant bacteria annually

## LACK OF DEVELOPMENT INCENTIVES

Manufacturers often lack incentives to develop new antibiotics because they are used sparingly—whenever medically appropriate—leading to a lower return on investment.

**\$800M +**



**10 YEARS**

AVERAGE INVESTMENT

in time and money to bring a new drug to market



**5 OUT OF 15**

APPROVED

ANTIBIOTICS SHELVED

Only 15 new antibiotics earned FDA approval in the past decade. Five were shelved due to poor financial performance.

## THE CYSTIC FIBROSIS EXPERIENCE

Respiratory infections are a hallmark of life with cystic fibrosis. Many people with cystic fibrosis live in fear of contracting an infection for which existing antibiotics are not effective.



**2 OUT OF 7**

of the most common infections in people with CF, including MRSA, are also serious threats to the general population according to the CDC.

THE FOUNDATION HAS DEDICATED

**\$109M**

in 3 years to address chronic infections



of research budget is dedicated to **PSEUDOMONAS + MRSA**

## STEPS TO A SUSTAINABLE MARKETPLACE

The CF Foundation is doing everything it can to put new infection treatments into the hands of patients, but our investment in research and development alone will not solve these marketplace challenges. The PASTEUR Act (S. 2076/H.R. 3932) will create a new post-market incentive structure that rewards companies who pursue and develop innovative new antibiotics and antifungals, and will lead to a more robust pipeline of products.



**INNOVATIVE THERAPIES**

WOULD QUALIFY FOR CONTRACT FUNDING THAT DELINKS FINANCIAL VALUE FROM USE



**POST-MARKET INCENTIVES**

ENSURE THAT INNOVATIVE PRODUCTS STAY ON MARKET FOR THOSE WHO NEED THEM



**STEWARDSHIP FUNDING**

ALLOWS THESE PRODUCTS TO BE EFFECTIVE FOR LONGER

**CONGRESS MUST PASS THE PASTEUR ACT (S. 2076/H.R. 3932) TO STRENGTHEN THE ANTIBIOTICS PIPELINE**